The subsequent potentiation of the Th2 response is strongly implicated in the development of AD, and dupilumab’s ability to suppress the IL-4/IL-13 signaling pathway makes it a suitable treatment option for this complex skin disorder [2]. In addition to attenuating these biomarkers, dupilumab has been shown to reduce T cell and dendritic cell activity and lesional epidermal hyperplasia, while increasing the expression of barrier and lipid metabolism genes, such as filaggrin [3]. This evidence concerns the gene IL4 and Alzheimer disease.